Pain treatment in arthritis-related pain: Beyond NSAIDs

Open Rheumatology Journal

Volumn 6, Issue 1, 2012, Pages 320-330

  van de Laar, Mart ^a   Pergolizzi Jr , Joseph V ^b,c   Mellinghoff, Hans Ulrich ^d   Merchante, Ignacio Morón ^e   Nalamachu, Srinivas ^f,g   O'Brien, Joanne ^h   Perrot, Serge ⁱ   Raffa, Robert B ^j  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Pain Center   (United States)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^e Centro de Salud Goya 2   (Spain)

^f UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^g International Clinic Research   (United States)

^h BEAUMONT HOSPITAL   (Ireland)

ⁱ HÔTEL DIEU   (France)

^j TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

more..

Author keywords

Analgesia; Fixed dose combination products; NSAID; Osteoarthritis; Paracetamol; Rheumatoid arthritis; Tramadol

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; BUPRENORPHINE; CAPSAICIN; CORTICOSTEROID; DICLOFENAC; DULOXETINE; LIDOCAINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PARACETAMOL; PARACETAMOL PLUS TRAMADOL; PLACEBO; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TAPENTADOL; TOPICAL AGENT; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ANALGESIA; ARTHRITIS; ARTICLE; BLURRED VISION; CHRONIC PAIN; COMPARATIVE EFFECTIVENESS; CONSTIPATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HAND OSTEOARTHRITIS; HEART DISEASE; HUMAN; KNEE OSTEOARTHRITIS; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NEWBORN EXFOLIATIVE DERMATITIS; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS; SEDATION; SIDE EFFECT; SKIN IRRITATION; SKIN MANIFESTATION; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

EID: 84883084058     PISSN: None     EISSN: 18743129     Source Type: Journal    
DOI: 10.2174/1874312901206010320     Document Type: Article

References (136)

1. Arendt-Nielsen L, Nie H, Laursen M, et al. Sensitization in patients with painful knee osteoarthritis. Pain 2010; 149: 573-81.
2. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain 2011; 152(3 Suppl): S2-15.
3. Dray A. New horizons in pharmacologic treatment for rheumatic disease pain. Rheum Dis Clin N Am 2008; 34: 481-505.
4. Peppin J. The marginalization of chronic pain patients on chronic opioid therapy. Pain Phys 2009; 12: 493-8.
5. Andersson HI. Increased mortality among individuals with chronic widespread pain relates to lifestyle factors: a prospective population-based study. Disabil Rehabil 2009; 31(24): 1980-7.
6. Torrance N, Elliott AM, Lee AJ, Smith BH. Severe chronic pain is associated with increased 10 year mortality. A cohort record linkage study. Eur J Pain 2010; 14(4): 380-6.
7. Andersson HI. The course of non-malignant chronic pain: a 12-year follow-up of a cohort from the general population. Eur J Pain 2004; 8(1): 47-53.
8. Brennan F, Carr D, Cousins M. Pain management: a fundamental human right. Anesth Analg 2007; 105: 205-21.
9. Fishman S. Recognizing pain management as a human right: a first step. Int Anesth Res Soc 2007; 105(1): 8-9.
10. Macpherson C. Undertreating pain violates ethical principles. J Med Ethics 2010; 35: 603-6.
11. Goldring M, Goldring S. Osteoarthritis. J Cell Physiol 2007; 213: 626-34.
12. Baker K, Grainger A, Niu J, et al. Relation of synovitis to knee pain using contrast-enhanced MRIs. Ann Rheum Dis 2010; 69(10): 1779-83.
13. Bonnet C, Walsh D. Osteoarthritis, angiogenesis and inflammation. Rheumatology 2005; 44: 7-16.
14. Ashraf S, Wibberley H, Mapp P, Hill R, Wilson D, Walsh D. Increased vascular penetration and nerve growth in the meniscus: a potential source of pain in osteoarthritis. Ann Rheum Dis 2011; 70: 523-9.
15. Mease P, Hanna S, Frakes E, Altman R. Pain mechanisms in osteoarthritis: understanding the role of central pain and current approaches to its treatment. J Rheumatol 2011; 38: 1546-51.
16. Mandl L. Treating the pain of osteoarthritis-where do we go from here? J Rheumatol 2011; 38(8): 1535-7.
17. Farrell M, Gibson S, McMeeken J, Helme R. Pain and hyperalgesia in osteoarthritis of the hands. J Rheumatol 2000; 27: 441-7.
18. Kosek E, Orderberg G. Lack of pressure pain modulation by heterotopic noxious conditioning stimulation in patients with painful osteoarthritis before, but not following, surgical pain relief. Pain 2000; 88(1): 69-78.
19. O'Driscoll S, Jayson M. Pain threshold analysis in patients with osteoarthritis of the hip. BMJ 1974; 3: 714-5.
20. Lee Y, Nassikas N, Clauw D. The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia. Arth Res Ther 2011; 13: 211-21.
21. Sofat N, Ejindu V, Kiely P. What makes osteoarthritis painful? The evidence for local and central pain processing. Rheumalogy 2011; 50: 2157-65.
22. Seed S, Dunican K, Lynch A. Osteoarthritis: a review of treatment options. Geriatrics 2009; 64(10): 20-9.
23. American Geriatric Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological Management of Persistent Pain in Older Persons. J Am Ger Soc 2009; 57(8): 1331-46.
24. Pergolizzi J, Böger R, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008; 4: 287-313.
25. Cheng H-Y, Penninger J. DREAMing about arthritic pain. Ann Rheum Dis 2004; 63(Suppl II): ii72-5.
26. Huskisson E, Hart F. Pain threshold and arthiritis. BMJ 1972; 4: 193-5.
27. Konttinen Y, Honkanen V, Gronblad M, Keinonen M, Santavirta N, Santavirta S. The relation of extraarticular tenderness to inflammatory joint disease and personality in patients with rheumatoid arthritis. J Rheumatol 1992; 19: 851-5.
28. Wendler J, Hummel T, Reissinger M, et al. Patients with rheumatoid arthritis adapt differently to repetitive painful stimuli compared to healthy controls. J Clin Neurosci 2001; 8(3): 272-7.
29. Perrot S. Should we switch from analgesics to the concept of pain modifying analgesic drugs (PMADS) in osteoarthritis and rheumatic chronic pain conditions? Pain 2009; 146: 229-30.
30. Kroenke K, Krebs E, Blair M. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hos Psych 2009; 31: 206-19.
31. Vonkeman H, Fernandes R, van de Laar M. Under-utilization of gastroprotective drugs in patients with NSAID-related ulcers. Int J Clin Pharmacol Ther 2007; 45(5): 281-8.
32. Bhatt D, Scheiman J, Abraham N, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52(18): 1502-17.
33. McNeil-NSAID Washington, D.C.: Food and Drug Adminstration; 2002 [cited 2012 September 9]; Available from: http://www.fda.gov/ohrms/dockets/ac/02/briefing/3882B2_02_McNeil-NSAID.htm
34. Antman E, Bennett J, Daugherty A, Furberg C, Roberts H, Taubert K. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007; 115(12): 1634-42.
35. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cylco-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 330: 1366.
36. Laine L, White W, Rostom A, Hochberg M. COX-2 selective inhibitors in the treatment of osteoarthritis. Semin Arthritis Rheum 2008; 38: 165-87.
37. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086.
38. Friedewald V, Bennett J, Christo J, et al. AJC Editor's consensus: Selective and nonselective nonsteroidal anti-inflammatory drugs and cardiovascular risk. Am J Cardiol 2010; 106(6): 873-84.
39. Gaziano J. Nonnarcotic analgesics and hypertension. Am J Cardiol 2006; 97(Suppl): 10E-6E.
40. Kearney P, Baigent C, Godwin J, Halls H, Emberson J, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332(7553): 1302-8.
41. Hunt R, Lanas A, Stichtenoth D, Scarpignato C. Myths and facts in the use of anti-inflammatory drugs. Ann Med 2009; 41: 423-37.
42. Chan F, Lanas A, Scheiman J, Berger M, Nguyen H, Goldstein J. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173-9.
43. Ofman J, MacLean C, Straus W, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 2002; 29(4): 804-12.
44. Boers M, Tangelder M, van Ingen H, Fort J, Goldstein J. The rate of NSAID-induced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of 12 randomised trials. Ann Rheum Dis 2007; 66(3): 417-8.
45. Diclofenac sodium 50mg tablets. Surrey, England: Electronic medicines compendium; 2005 [updated December 2008; cited 2012 September 9]; Available from: http://www.medicines.org.uk/emc/medicine/22653#INCOMPATIBILITIES
46. Anadin ibuprofen 200mg tablets. Surrey, England: Electronic Medicines Compendium; 2011 [updated March 31, 2011; cited 2012 September 9]; Available from: http://www.medicines.org.uk/EMC/medicine/15681/SPC/Anadin+Ibuprofen+200mg+Tablets/
47. Naproxen 250mg tablets. Surrey, England: Electronic Medicines Compendium; 2011 [updated April 18, 2012; cited 2012 September 9]; Available from: http://www.medicines.org.uk/emc/medicine/23037/SPC#INCOMPATIBILITIES
48. Celebrex 100mg & 200mg capsules. Surrey, England: Electronic Medicines Compendium; 2011 [updated May 3, 2011; cited 2012 September 9]; Available from: http://www.medicines.org.uk/emc/medicine/14534#INCOMPATIBILITIES
49. NICE. Rheumatoid arthritis: the management of rheumatoid arthritis in adults. London: NICE; 2009 [cited 2010 December 18]; Available from: http://www.nice.org.uk/nicemedia/live/12131/43327/43327.pdf
50. NICE. Osteoarthritis: the care and management of osteoarthritis in adults. London: National Institute for Health and Clinical Excellence; 2008; Available from: http://www.nice.org.uk/nicemedia/pdf/CG59NICEguideline.pdf [cited 2011 May 13]
51. Hochberg M, Dougados M. Pharmacological therapy of osteoarthritis. Best Pract Res Clin Rheumatol 2001; 15(4): 583-93.
52. Watkins P, Kaplowitz N, Slattery J, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006; 296(1): 87-93.
53. Albertson T, Walker V, Stebbins M, Ashton E, Owen K, Sutter M. A population study of the frequency of high-dose acetaminophen prescribing and dispensing. Ann Pharmacother 2010; 44: 1191-5.
54. Hornsby L, Whitley H, Hester E, Thompson M, Donaldson A. Survey of patient knowledge related to acetaminophen recognition, dosing, and toxicity. J Am Pharm Assoc 2010; 50(4): 485-9.
55. Sudano I, Flammer A, Périat D, et al. Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation 2010; 122(18): 1789-96.
56. Forman J, Rimm E, Curhan G. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007; 167(4): 394-9.
57. Brandt K, Mazzuca S, Buckwalter K. Acetaminophen, like conventional NSAIDs, may reduce synovitis in osteoarthritic knees. Rheumatology 2006; 45: 1389-94.
58. Flood J. The role of acetaminophen in the treatment of osteoarthritis. Am J Manag Care 2010; 16: S48-S54.
59. WHO. WHO's pain ladder. Geneva, Switzerland: World Health Organization; 1986 [updated 2011; cited 2012 June 15]; Available from: http://www.who.int/cancer/palliative/painladder/en/
60. Raffa R, Friederichs E. The basic science aspect of tramadol hydrochloride. Pain Rev 1996; 3: 249-71.
61. Cepeda M, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis. Cochrane Datab Syst Rev 2006; (3): CD005522.
62. Rosenberg M. The role of tramadol ER in the treatment of chronic pain. Int J Clin Pract 2009; 63(10): 1531-43.
63. Adams E, Breiner S, Cicero T, et al. A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J Pain Symptom Manage 2006; 31(5): 465-76.
64. Tramadol hydrochloride 50mg capsules. Surrey, England: Datapharm Communications Ltd; 2011 [updated 2 February 2011; cited 2011 December 15]; Available from: http://www.medicines.org.uk/emc/medicine/24186/SPC/tramadol%20hydrochloride%2050mg%20caps ules/
65. Trescot A, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Phys 2008; 11: S5-S62.
66. Birnbaum H, White A, Schiller M, Waldman T, Cleveland J, Roland C. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med 2011; 12(4): 657-67.
67. Joranson D, Gilson A. Wanted: a public health approach to prescription opioid abuse and diversion. Pharmacoepidemiol Drug Saf 2006; 15: 632-4.
68. Ling W, Mooney L, Hillhouse M. Prescription opioid abuse, pain and addiction: clinical issues and implications. Drug Alcohol Rev 2011; 30: 300-5.
69. Minozzi S, Amato L, Davoli M. Development of dependence following treatment with opioid analgesics for pain relief: a systematic review. Addiction 2012; [Epub ahead of print].
70. Schneider J, Matthews M, Jamison R. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse? CNS Drugs 2010; 24(10): 805-10.
71. Raffa R, Pergolizzi J. Opioid formulations designed to resist/deter abuse. Drugs 2010; 70(13): 1657-75.
72. Furlan A, Sandoval J, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006; 174: 1589-94.
73. Gianni W, Madaio A, Ceci M, et al. Transdermal buprenorphine for the treatment of chronic noncancer pain in the oldest old. J Pain Symptom Manage 2011; 41(4): 707-14.
74. Vadivelu N, Hines R. Management of chronic pain in the elderly: focus on transdermal buprenorphine. Clin Interv Aging 2008; 3(3): 421-30.
75. Afilalo M, Etropolski M, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo-and active-controlled phase III study. Clin Drug Investig 2010; 30(8): 489-505.
76. Wild J, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 2010; 10(5): 416-27.
77. Lipman A. Treatment of chronic pain in osteoarthritis: do opioids have a clinical role? Curr Rheum Rep 2001; 3: 513-9.
78. Pancrazio J, Kamatchi G, Roscoe A, Lynch Cr. Inhibition of neuronal Na+ channels by antidepressant drugs. J Pharmacol Exp Ther 1998; 284(1): 208-14.
79. Bechmann L, Best J, Haag S, Leineweber K, Gerken G, Holtmann G. Serotoninergic and non-serotoniergic effects of two tricyclic antidepressants on visceral nociception in a rat model. Scand J Gastroenterol 2009; 44(6): 680-6.
80. Macfarlane J, Jalali S, Grace E. Trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness. Curr Med Res Opin 1986; 10: 89-93.
81. Sarzi Puttini P, Cazzola M, Boccassini L, et al. A comparison of dothiepin versus placebo in the treatment of pain in rheumatoid arthritis and the association of pain with depression. J Int Med Res 1988; 16: 331-7.
82. Frank R, Kashani J, Parker J, et al. Antidepressant analgesia in rheumatoid arthritis. J Rheumatol 1988; 15: 1632-8.
83. Ash G, Dickens C, Creed F, Jayson M, Tomenson B. The effects of dothiepin on subjects with rheumatoid arthritis and depression. Rheumatology 1999; 38: 959-67.
84. Perrot S, Javier R-M, Marty M, LeJeunne C, Laroche F. Is there any evidence to support the use of anti-depressants in painful rheumatological conditions? Systematic review of pharmacological and clinical studies. Rheumatology 2008; 47: 1117-23.
85. Dworkin R, O'Connor A, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85(3 Suppl): S3-S14.
86. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012; 60(4): 616-31.
87. Uchitel OD, Di Guilmi MN, Urbano FJ, Gonzalez-Inchauspe C. Acute modulation of calcium currents and synaptic transmission by gabapentinoids. Channels 2010; 4(6): 490-6.
88. Rahman W, Bauer C, Bannister K, Vonsy J, Dolphin A, Dickenson A. Descending serotonergic facilitation and the antinociceptive effects of pregabalin in a rat model of osteoarthritic pain. Mol Pain 2009; 7(5): 45.
89. Moore R, Straube S, Wiffen P, Derry S, McQuay H. Pregabalin for acute and chronic pain in adults. Cochrane Datab Syst Rev 2009; 8(3): CD007076.
90. Chappell A, Ossanna M, Liu-Seifert H, et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain 2009; 146: 253-60.
91. Watanabe S, Bruera E. Corticosteroids as adjuvant analgesics. J Pain Symptom Manage 1994; 9: 442-5.
92. den Uyl D, van Raalte DH, Nurmohamed MT, et al. Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: Balance between diabetogenic effects and inflammation reduction. Arthritis Rheum 2012; 64(3): 639-46.
93. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2010; 62(11): 1515-26.
94. Franchimont D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann NY Acad Sci 2004; 1024: 124-37.
95. National Health Service UK. Corticosteroids side effects. Available from: http://www.nhs.uk/Conditions/Corticosteroid-%28drugs%29/Pages/Sideeffects.aspx, [Cited 2012 September 12];
96. Haynes S, Gemmell H. Topical treatments for osteoarthritis of the knee. Clin Chiroprac 2007; 10: 126-38.
97. Bookman A, Williams K, Shainhouse J. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ 2004; 171(4): 333-8.
98. Simon L, Grierson L, Naseer Z, Bookman A, Shainhouse J. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain 2009; 143: 238-45.
99. Roth S, Shainhouse J. Efficacy and safety of a topical diclofenac solution (Pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Arch Intern Med 2004; 164: 2017-23.
100. Altman R, Dreiser R-L, Fisher C, Chase W, Dreher D, Zacher J. Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009; 36: 1991-9.
101. Baer P, Thomas L, Shainhouse Z. Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886]. BMC Musculoskelet Disord 2005; 6: 44-53.
102. Tugwell P, Wells G, Shainhouse J. Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 2004; 31: 2002-12.
103. Burch F, Codding C, Patel N, Sheldon E. Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients. A prospective, multicenter, open-label effectiveness trial. Osteoarthritis Cartilage 2004; 12(3): 253-5.
104. Galer B, Sheldon E, Patel N, Codding C, Burch F, Gammaitoni A. Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritis. Curr Med Res Opin 2004; 20(9): 1455-8.
105. Gammaitoni A, Galer B, Onawola R, Jensen M, Argoff C. Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale. Curr Med Res Opin 2004; 20(Suppl 2): S13-S9.
106. Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012; 64(4): 455-74.
107. Altman RD, Barthel HR. Topical therapies for osteoarthritis. Drugs 2011; 71(10): 1259-79.
108. Raffa R. Pharmacological aspects of successful long-term analgesia. Clin Rheumatol 2006; 25(Suppl 1): S9-S15.
109. Raffa R, Clark-Vetri R, Tallarida R, Wertheimer A. Combination strategies for pain management. Expert Opin Pharmacother 2003; 4: 1697-708.
110. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010; 18(4): 476-99.
111. Choi C, Song J, Kang Y, et al. A 2-week, multicenter, randomized, double-blind, double-dummy, add-on study of the effects of titration on tolerability of tramadol/acetaminophen combination tablet in Korean adults with knee osteoarthritis pain. Clin Ther 2007; 29(7): 1381-9.
112. Raffa R, Friderichs E, Reimann W, Shank R, Codd E, Vaught J. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 1992; 260(1): 275-85.
113. Filitz J, Ihmsen H, Günther W, et al. Supra-additive effects of tramadol and acetaminophen in a human pain model. Pain Manage Nursing 2008; 136(3): 262-70.
114. Magliano M, Morris V, Eds. Use of analgesics in rheumatology. London: Arthritis Research Campaign 2002.
115. Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 2000; 43(2): 378-85.
116. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66(1): 34-45.
117. Luqmani R, Hennell S, Estrach C, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology 2009; 48(4): 436-9.
118. Ramiro S, Radner H, van der Heijde D, et al. Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev 2011; (10): CD008886.
119. Zhang W, Moskowitz R, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16(2): 137-62.
120. Luqmani R, Hennell S, Estrach C, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology 2006; 45(9): 1167-9.
121. Vermeer M, Kuper HH, Hoekstra M, et al. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum 2011; 63(10): 2865-72.
122. Schipper LG, Vermeer M, Kuper HH, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis 2012; 71(6): 845-50.
123. Raffaeli W, Pari C, Corvetta A, et al. Oxycodone/acetaminophen at low dosage: an alternative pain treatment for patients with rheumatoid arthritis. J Opioid Manag 2010; 6(1): 40-6.
124. Corsinovi L, Martinelli E, Fonte G, et al. Efficacy of oxycodone/acetaminophen and codeine/acetaminophen vs conventional therapy in elderly women with persistent, moderate to severe osteoarthritis-related pain. Arch Gerontol Ger 2009; 49: 387-2.
125. Mullican W, Lacy J. Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial. Clin Ther 2001; 23(9): 1429-45.
126. Palangio M, Damask M, Morris E, et al. Combination hydrocodone and ibuprofen versus combination codeine and acetaminophen for the treatment of chronic pain. Clin Ther 2000; 22(7): 879-92.
127. Conaghan P, O'Brien C, Wilson M, Schofield J. Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee: a randomised trial. Osteoarthritis Cartilage 2011; 19: 930-8.
128. Emkey R, Rosenthal N, Wu S, Jordan D, Kamin M. Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. J Rheumatol 2004; 31(1): 150-6.
129. Park K-S, Choi J-J, Kim W-U, Min J-K, Park S-H, Cho C-S. The efficacy of tramadol/acetaminophen combination tablets (Ultracet®) as add-on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti-inflammatory drug (NSAID). Clin Rheumatol 2012; 31(2): 317-23.
130. Alwine L. Long-term (2-year) analgesic efficacy of tramadol/ acetaminophen tablets. European League Against Rheumatism (EULAR) Congress 2000; Nice, France 2000. p. Poster 301.
131. Rosenthal N, Silverfield J, Wu S, Jordan D, Kamin M. Tramadol/acetaminophen combination tablets for the treatment of pain associated with osteoarthritis flare in an elderly patient population. J Am Geriatr Soc 2004; 52(3): 374-80.
132. Silverfield J, Kamin M, Wu S, Rosenthal N. Tramadol/ acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double-blind, placebo-controlled, parallel-group, add-on study. Clin Ther 2002; 24(2): 282-97.
133. Lee E, Lee E, Park B, et al. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial. Clin Ther 2006; 28(12): 2052-60.
134. Doherty M, Hawkey C, Goulder M, et al. A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community-derived people with knee pain. Ann Rheum Dis 2011; 70: 1534-41.
135. Pareek A, Chandurkar N, Ambade R, Chandanwale A, Bartakke G. Efficacy and safety of etodolac-paracetamol fixed dose combination in patients with knee osteoarthritis flare-up: a randomized, double-blind comparative evaluation. Clin J Pain 2010; 26: 561-6.
136. Pareek A, Chandurkar N, Sharma V, Desai M, Kini S, Bartakke G. A randomized, multicentric, comparative evaluation of aceclofenac-paracetamol combination with aceclofenac alone in Indian patients with osteoarthritis flare-up. Expert Opin Pharmacother 2009; 10(5): 727-35.